Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CD19/CD22 Bispecific CAR-T Cell Therapy in R/R Large B-cell Lymphoma
NCT07461831Phase 2Completed
- Sponsor
- Beijing Tongren Hospital
- Start
- Feb 2022
- Primary completion
- Apr 2026
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of CAR2219 in diffuse large B-cell lymphoma (DLBCL), sponsored by Beijing Tongren Hospital. Primary endpoint: Objective Response Rate at 3 months. Started Feb 2022; status: completed.
02
Drugs
CAR2219
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT07461831.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07461831.